Blue Shield of California wants to pay for GLP-1 drugs through a flat monthly fee for access and a bonus when members see results.
Paul Markovich, CEO of Ascendiun, the parent company of Blue Shield, laid out the idea in an interview with Bloomberg published Nov. 18, describing a model where the insurer would pay manufacturers a set amount each month to make the drugs available to members, then add a second payment tied to results such as weight loss or better blood sugar control. Mr. Markovich told the news outlet that Eli Lilly and Novo Nordisk know Blue Shield is interested in such a deal, but terms are not final and regulatory changes could be needed to make it a reality.
The proposal comes as Mr. Markovich has been pushing for the industry to move away from drug rebates. At Becker’s Fall Payer Issues Roundtable in early November, he said plans that believe they’ve negotiated strong rebate deals are still seeing pharmacy costs climb, because list prices are rising about 12% a year while the net prices drugmakers actually collect rise about 3%, with rebates covering the gap.
“This is all funny money,” he said. “They’re just inflating the list price and then sending bigger rebates back. And then you think you’re getting a great deal but the pharmacy trend keeps going crazy.”
In 2023, Blue Shield announced it would drop CVS Caremark as its sole pharmacy benefit manager to fix what it called a “broken prescription drug system,” splitting those services among several companies, including Amazon Pharmacy and Abarca. The model, called Pharmacy Care Reimagined, went live in 2025 with a goal of saving up to $500 million a year. Under the model, CVS manages Blue Shield’s specialty drug network, while Prime Therapeutics negotiates with drugmakers.
Nearly two years in, Mr. Markovich said Blue Shield has saved roughly $150 million of that target annually through lower administrative costs and early savings. Much of the rest depends on the piece that has proven hardest: negotiating net prices directly with drugmakers with no rebates involved.
“It’s been a longer road than I would have hoped,” he said at the Becker’s roundtable. He told Bloomberg the insurer has direct pricing deals for fewer than 10 medications.
But Mr. Markovich added that he’s “a little more optimistic that it’s not just us doing it” now that new laws and settlements are pushing the largest PBMs toward net pricing. Those include the federal spending package enacted in February, which will require PBMs to pass all rebates through to employer health plans, and California’s PBM law, signed last year, which has required a pass-through pricing model since Jan. 1. The Labor Department also finalized a rule last month that will require PBMs to disclose their full compensation, including rebates, to large self-insured plans.
Other reported pharmacy gains at Blue Shield have come from drugs that face cheaper competition. Hayley Park, PharmD, the company’s chief pharmacy officer, said on the Becker’s Payer Issues Podcast this month that about 85% of the insurer’s Humira use has shifted to biosimilars. She noted that shift was slow at first because favoring cheaper drugs put branded rebates at risk.
“When you think about it, you finally have competition, but the rebate system could penalize us for using it,” Dr. Park said.
Blue Shield’s net price for the biosimilar, which it buys directly from Fresenius Kabi under a deal announced in 2024, began at about $500, compared with Humira’s list price of about $7,000, she said.
The insurer has taken the same approach with generic specialty drugs through CivicaScript, a nonprofit generic drugmaker Blue Shield helped launch with 18 other Blue plans in 2020. Dr. Park cited price reductions of 41% for abiraterone, a prostate cancer drug, and 64% for capecitabine, an oral chemotherapy drug. Because those discounts apply upfront, members also pay less at the pharmacy counter.
“We’re not just lowering drug costs; we’re also changing who benefits from the savings and when those benefits occur,” she added.
Dr. Park expects a new state law, SB 1094, to push biosimilar use further by giving state-regulated health plans and pharmacists more room to substitute biosimilars for brand-name biologics. The California Association of Health Plans, which sponsored the bill, said a state analysis estimated it would save residents nearly $88 million a year in premiums.
“We believe this bill will markedly transform the ability to convert patients to clinically equivalent biosimilar medications,” Dr. Park said, though she noted that not every patient can or should be switched just because a cheaper option exists.
GLP-1s have not lent themselves to the same playbook, and since 2025 Blue Shield has limited coverage of certain weight-loss drugs for some commercial members.
For drugs that lack cheaper competition, Mr. Markovich said the industry needs an entity that would assess their value and set a threshold price. Drugmakers could still charge more, he added, but “you might not have a patent,” and competition could be brought in to lower the price.
“Something along those lines is what we’re proposing,” he said. “Let’s sit down with pharma as a group and see if we can hash something out as an industry, and if not, put it in a law.”
